Acute and preventive treatment of menstrual migraine: a meta-analysis

• Published in: Journal of headache and pain Vol. 25; no. 1; pp. 143 - 13
• Main Authors: Khoo, Cindy Ciat-Wuah, Liu, Chan-Cheng, Lu, Michael, Huang, Yu-Chen, Weng, Hsing-Yu
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 04.09.2024; Springer Nature B.V; BMC
• Subjects: Acute treatment; Analgesics; Calcitonin gene-related peptide; CGRP monoclonal antibody; Female; Gender-Specific Aspects of Headache; Headache; Headaches; Humans; Internal Medicine; Medicine; Medicine & Public Health; Menstrual migraine; Menstruation; Meta-analysis; Migraine; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Monoclonal antibodies; Neurology; Pain; Pain Medicine; Placebos; Prevention; Preventive treatment; Randomized Controlled Trials as Topic; Sumatriptan; Triptans; Tryptamines - therapeutic use; Acute treatment; Triptans; CGRP monoclonal antibody; Menstrual migraine; Preventive treatment; Meta-analysis
• ISSN: 1129-2377; 1129-2369; 1129-2377
• DOI: 10.1186/s10194-024-01848-6

Background and objectives About a quarter of migraine cases among women have menstrual migraine (MM), which is usually more severe, longer lasting, and less responsive to treatment than typical migraine. Randomized controlled trials (RCTs) have evaluated the efficacy of several medication in the acute and preventive treatment of MM; this meta-analysis compared the effectiveness of these treatments. Methods We conducted systematic searches in the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase databases. The primary outcomes of acute treatment trials were pain relief at 2 and 24 h after treatment compared with placebo or another treatment. The three endpoints we checked for studying MM prevention were: no recurrence of headaches each month, a 50% reduction in monthly migraine days from baseline, and a decrease in the mean number of headache days per month. Results Out of 342 studies, 26 RCTs met the criteria. Triptans, combined with or without other analgesics, were superior to placebo in providing pain relief in the acute treatment and prevention of MM. Among the treatments, sumatriptan and lasmiditan demonstrated superior pain relief at 2 h (OR: 4.62) and 24 h (OR: 4.81). Frovatriptan exhibited effectiveness in preventing headache recurrence, whereas galcanezumab and erenumab displayed significant preventive benefits in reducing headache days per month. Conclusion Sumatriptan and lasmiditan are effective first-line treatments for acute MM. For prevention, frovatriptan may be the more effective of triptans. Compared with triptans, CGRP monoclonal antibodies, here including erenumab and galcanezumab, are more effective in reducing headache days, and therefore, in preventing MM.